clinical trial · NCT05712902
Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)
Non-Small Cell Lung CancerSunvozertinib
brief summary
This is a Phase II, single-arm, multi-center clinical study to evaluate the anti-tumor efficacy, safety, tolerability and pharmacokinetics of Sunvozertinib in participants with locally advanced or metastatic NSCLC carrying EGFR exon 20 insertion mutations whose disease has progressed on prior platinum-based chemotherapy
started
Jul 19, 2021
primary completion
Oct 17, 2022
completion
Dec 31, 2025
last updated
Dec 30, 2024
official title
A Phase II, Single Arm, Multicenter Study to Evaluate Anti-tumor Activity, Safety, Tolerability and Pharmacokinetics of DZD9008 in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol